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Abstract 1 
 2 
Background:  The role of adiponectin in mediating gonadal status and bone health in weight-3 
stable healthy adult female athletes with secondary amenorrhea has not yet been described.  4 
Methods: Using a prospective observational study, age matched premenopausal women were 5 
studied, including: 1) sedentary ovulatory women (SedOv; n=10), 2) exercising ovulatory women 6 
(ExOv; n=15), and 3) exercising amenorrheic women (ExAmen; n=9).  Primary outcome 7 
measures included serum total adiponectin and daily urinary estrogen (E1G) levels, expressed as 8 
area under the curve (AUC), body fat distribution, and bone mineral density (BMD).  Serum 9 
leptin, ghrelin, total triiodothyronine (TT3), insulin, and resting energy expenditure (REE) were 10 
also determined.   11 
Results: The women in this study did not differ in age (25.3±1.4 years; mean ± SEM), height 12 
(164±1 cm), weight (57.7±1.0 kg) and BMI (21.5±0.4 kg/m2).  Exercising women had a higher fat 13 
free mass (FFM), lower fat mass (FM) and lower serum leptin concentrations (p<0.05) compared 14 
to sedentary women.  Adiponectin and ghrelin levels were higher (p<0.05), and TT3 (p=0.019), 15 
urinary E1G AUC (p=0.002) lower in ExAmen compared with ExOv and SedOv. Total and L1-16 
L4 BMD were lower (p<0.05) in ExAmen compared with ExOv.  Stepwise linear regression 17 
identified trunkal FM as the strongest predictor of log adiponectin adjusted for FM (F=23.54, 18 
p<0.001).  L1-L4 BMD was predicted by log adiponectin and E1G AUC (F=9.856, p=0.045). 19 
Total BMD was predicted by log adiponectin (F=7.948, p=0.009). TT3 was the strongest 20 
predictor of E1G AUC (F=9.885, p=0.004).   21 
Conclusions: Hypoestrogenic adult female athletes with secondary amenorrhea demonstrate 22 
elevated circulating adiponectin relative to FM in association with impaired bone health. Estrogen 23 
exposure was predicted by TT3, but not adiponectin. These findings suggest that nutritionally 24 
regulated hormones may mediate gonadal status, and that adiponectin and estrogen, either 25 
  
3 
independently or in combination, may mediate bone health in adult amenorrheic physically active 1 
women.  2 
  
4 
1.  INTRODUCTION 1 
 In exercising women, energy deficiency, a consequence of inadequate caloric intake 2 
relative to exercise energy expenditure, has been proposed as the causal mechanism of menstrual 3 
disturbances [1, 2]. While not all exercising women experience symptomatic menstrual 4 
disturbances, between 2-44 % of female athletes have reported amenorrhea, the most severe 5 
menstrual disorder [3, 4]. Secondary to inadequate caloric intake, energy deficient amenorrheic 6 
athletes demonstrate hypoestrogenemia and a hypometabolic state, including suppressed 7 
concentrations of glucose, leptin, insulin, and total triiodothyronine (TT3) and elevated levels of 8 
ghrelin and peptide YY [5-10].  In adolescent amenorrheic athletes, elevated ghrelin and reduced 9 
leptin concentrations predict suppressed levels of gonadal steroids [8].  It is not known if these, or 10 
other factors, such as adiponectin, similarly predict gonadal status in adult amenorrheic athletes.   11 
Adiponectin is an adipose tissue-specific secretory protein that is expressed exclusively 12 
in differentiated adipocytes [11]. In contrast to other adipokines, such as tumor-necrosis factor 13 
and interleukin-6, which are upregulated with increasing adiposity, adiponectin concentrations 14 
correlate negatively with obesity and insulin resistance [12, 13]. Conversely, adiponectin 15 
concentrations have been reported to correlate both positively [14] and negatively [15] with low 16 
body weight, i.e., anorexia nervosa.  Reasons for discrepancy in anorexia nervosa are unclear, but 17 
may be related, in part to body-fat distribution.  For example, recent in vitro evidence 18 
demonstrates that the rate of adiponectin secretion is approximately threefold higher from visceral 19 
compared with subcutaneous fat, suggesting that distribution of body fat rather than total fat 20 
amount may be important [16]. Examination of possible relationships between fat-deposition site 21 
and circulating adiponectin concentrations in premenopausal eumenorrheic and amenorrheic 22 
women has not yet been reported. 23 
 The regulatory role and consequences of altered adiponectin metabolism are not yet well 24 
described. Studies indicate, however, that metabolic rate may be increased and bone health 25 
impaired by hypo- and hyper-adiponectinemia, respectively [14, 17].  Several studies have also 26 
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demonstrated that women have higher adiponectin levels compared to men, independent of body 1 
fat mass or body fat distribution [13, 18], suggesting that circulating gonadal steroids may affect 2 
adiponectin secretion [19].  To date, however, there have been no reports describing whether 3 
estrogen exposure, as assessed by daily urinary analysis of ovarian steroids over time, is mediated 4 
by nutritionally regulated hormones, such as adiponectin, in young adult physically active 5 
amenorrheic women.  Such assessment may increase the ability to detect estrogenic associations, 6 
when present, compared with one-time sample serum measures of estradiol. 7 
 The objectives of the current study were threefold.  In eumenorrheic ovulatory athletes 8 
and amenorrheic athletes, to explore: 1) the relationship between adiponectin concentrations and 9 
gonadal status (i.e., estrogen exposure) as assessed via daily urinary measures over time; 2) the 10 
relationship between adiponectin and nutritionally mediated factors known to be altered in 11 
response to energy deficiency, including TT3 and resting energy expenditure; and 3) the 12 
associations between adiponectin, body composition, body fat distribution and bone health.  We 13 
hypothesized that compared to estrogen replete women, hypoestrogenic physically active adult 14 
premenopausal women with energy deficiency associated amenorrhea (EDAA) would 15 
demonstrate elevated serum adiponectin concentrations, and that these concentrations would 16 
predict gonadal status and bone health. We further postulated that adiponectin concentrations 17 
would be negatively associated with nutritionally mediated factors known to be altered in 18 
response to energy deficiency.  Finally, we hypothesized that central (i.e., visceral) adipose mass 19 
would demonstrate stronger associations with adiponectin compared with peripheral (i.e., 20 
subcutaneous) adipose deposition.   21 
 22 
2.  METHODOLOGY 23 
2.1  Participants   24 
Participants were recruited by posters. Physical activity status was required to have been 25 
consistent for the previous 6 months. Eligibility criteria for the study included: 1) age 18 to 35 26 
  
6 
yrs; 2) good health determined by a medical exam; 3) no chronic illness, including 1 
hyperprolactinemia, polycystic ovarian syndrome, and thyroid disease; 4) stable self reported 2 
menstrual status (i.e., same menstrual status) over the preceding 3 months, with menstruating 3 
women having cycle lengths between 25-35 days, and athletic women with secondary 4 
amenorrhea having not menstruated for at least 90 consecutive days [4]; 5) non-smoking; 6) not 5 
currently dieting and weight stable for the preceding 3 months, as determined by self-report; 7) 6 
absence of hormonal therapy for at least 12 months; 8) no history or current clinical diagnosis of 7 
eating disorders and 9) no other contraindications that would preclude participation in the study.  8 
The study was approved by the institutional committee on human research by the Ethics Review 9 
Board at the University of Toronto, and confirmed to the standards set by the latest revision of the 10 
Declaration of Helsinki.  All volunteers signed an approved informed consent document. 11 
 12 
2.2  Experimental Design   13 
We originally conducted a prospective observational study on a rolling basis over 2-3 14 
years to examine relationships between physical activity, metabolism, cardiovascular health and 15 
reproductive function.  Fifty-two women completed the entire study, with 34 of these 52 being 16 
included in the current post-hoc study.  The relationship between estrogen exposure and 17 
numerous metabolic and nutritionally regulated hormones on cardiovascular function in a subset 18 
of these women have previously been described by our laboratory [6, 20].  However, the potential 19 
for nutritionally regulated hormones, specifically adiponectin, and indices of metabolic status, 20 
namely TT3 and REE, to predict gonadal status has not been previously reported by our group.   21 
  22 
2.3  Observational Time Periods  23 
Menstruating women were monitored for 2 to 3 consecutive menstrual cycles, and 24 
amenorrheic women were monitored for 2 to 3 consecutive 30-day monitoring periods.  All 25 
measures, except urinary measures which were assessed daily, were obtained during the early 26 
  
7 
follicular phase (days 2-6) across two-to three menstrual cycles for menstruating women, and 1 
during days 1-6 of each 30-day monitoring period for amenorrheic women.  The mean of these 2 
measures were used in statistical analyses. 3 
 4 
2.4  Exercise and Menstrual Status  5 
Exercise status was defined as “sedentary” when purposeful exercise was less than 2 6 
hours per week and “exercising” when purposeful exercise was more than 2 hours per week [21].  7 
Purposeful exercise, defined as exercise that elicited a heart rate (HR) greater than 55% of 8 
maximal HR (220 minus age) for 3 minutes or more, was documented in exercise logs [6].  HR 9 
was determined by the subject counting heart beats during a 10 second period of carotid artery 10 
palpation after each exercise bout.  In conjunction with the hours of exercise activity criterion, we 11 
also utilized a VO2 max of <40 ml/kg/min to reflect sedentary status and 40 ml/kg/min or greater 12 
to reflect exercising status consistent with published data of this parameter [22].  13 
Menstrual status was determined from daily first morning void urine samples collected by 14 
all participants for the duration of the study period. Urine samples were assayed for luteinizing 15 
hormone (LH), pregnanediol 3-glucuronide (PdG), and estrone 3-glucuronide (E1G) to assess 16 
ovulatory status and estrogen exposure.  Our group has previously detailed the criteria for 17 
detection of positive ovulation and menstrual status [6]. 18 
 19 
2.5  Estrogen Exposure  20 
Calculation of estrogen exposure over time has been described, in detail, elsewhere [6].  21 
Briefly, using daily urinary estrogen levels, estrogen exposure over time was calculated by the 22 
trapezoidal area under the curve method across two to three menstrual cycles for menstruating 23 
women, and across two to three 30-day monitoring periods for amenorrheic women.  24 
 25 
 26 
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2.6  Study Groups   1 
Three groupings were retrospectively established based on exercise and menstrual status: 2 
1) sedentary women with ovulatory menstrual cycles (SedOv; n=10), 2) exercising women with 3 
ovulatory menstrual cycles (ExOv; n=15), and 3) exercising women with amenorrhea, defined as 4 
cessation of menses for >90 d (ExAmen; n=9) [23]. 5 
 6 
2.7  Anthropometric Measures  7 
Average total body mass was determined from weekly measures to the nearest 0.1 kg on 8 
a physician’s balance scale (Detecto, Webb City, MO). Height was measured to the nearest 1.0 9 
cm at the beginning of the study period. Body mass index (BMI) was calculated (kg/m2).  10 
 11 
2.8  Body Composition and Bone Mineral Density  12 
Dual-energy x-ray absorptiometry (DXA) was utilized to determine body composition 13 
and bone mineral density (BMD) once during the study by a trained technician (Prodigy, General 14 
Electric Lunar Corporation, Madison, WI, enCORE 2002 software, version 6.50.069).  Whole 15 
body and lumbar (L1-L4) BMD (g/cm2) and Z-scores were determined. Central fat mass (kg) was 16 
determined from the fat mass measured in the trunk, and peripheral fat mass was determined as 17 
the sum of fat mass measured in the arms and legs. BMD (g/cm2) was determined at the spine 18 
(L1–L4) and for total body by an ISCD certified operator. A 28 subject precision study was 19 
performed in premenopausal women and precision was 0.6 and 0.7 % at the total body and 20 
lumbar spine, respectively. The DXA scanner has a precision of < 1% coefficient of variation for 21 
body composition measurements.  22 
 23 
2.9  Resting Energy Expenditure 24 
Using the Weir equation [24], REE (kcal day-1) was determined by indirect calorimetry 25 
with a ventilated hood system (SensorMedics Vmax Series, Yorba Linda, CA).  After a 45 minute 26 
  
9 
supine rest period, REE measures were taken for 30 minutes between 0830 and 1100. Oxygen 1 
consumption (VO2; mL min-1) and carbon dioxide production (VCO2; mL min-1) were measured 2 
every 20-seconds during REE measurement. To calculate REE, data for VO2 and VCO2 were 3 
only used if steady state was attained for a minimum of 10 minutes, and respiratory quotient 4 
values did not varying by more than 10%.  REE adjusted for fat free mass (FFM) was calculated 5 
to adjust metabolic rate for metabolically active tissue (i.e., muscle).       6 
 7 
2.10  Peak Aerobic Capacity  8 
VO2 peak was measured once by a progressive treadmill test to volitional exhaustion. 9 
Expired gases were collected continuously to measure inspired air volumes and to analyze breath-10 
by-breath samples (Moxus Modular VO2 System, Applied Electrochemistry Inc., Pittsburgh, PA). 11 
 12 
2.11  Serum Measures  13 
Serum was analyzed for total adiponectin, leptin, total ghrelin, total triiodothyronine 14 
(TT3) and insulin. Eight-hour fasted blood samples were collected between 0730 and 1000 hr.  15 
Serum samples were immediately stored at -80°C until analyses were run.  Total adiponection 16 
(i.e., low, medium, and high molecular weight) was analyzed using an enzyme immunoassay 17 
technique (Quantikine Assay Kit, DRP300, R&D Systems Inc., Minneapolis, MN).  Sensitivity 18 
was 0.246 ng/mL.  Leptin was analyzed using a direct sandwich enzyme-linked immunosorbent 19 
assay (ELISA, Linco Research, Inc., St. Charles, MO).  Analytical sensitivity was 0.5 ng/mL. 20 
Total serum ghrelin was analyzed using radioimmunoassay techniques (Linco research Inc., St 21 
Charles, MO). Analytical sensitivity of the ghrelin assay was 2.97 pmol L-1.  Serum insulin and 22 
TT3 were analyzed using a chemiluminescence-based immunoassay analyzer (Immulite, 23 
Diagnostics Products Corporation, Los Angeles, CA). Analytical sensitivity for the insulin assay 24 
was 13.89 pmol L-1, and for the TT3 assay was 0.54 nmol L-1.  All inter- and intra-assay 25 
coefficients of variation have previously been reported by our group [6, 20]. 26 
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 1 
2.12  Urinary Measures  2 
Measures of daily urinary metabolites were determined using microtiter plate competitive 3 
enzyme immunoassays to detect pregnanediol 3-glucuronide (PdG), and estrone 3-glucuronide 4 
(E1G).  Detailed methods for these immunoassays have been described previously [6, 20].  The 5 
inter-assay coefficients of variation for high and low internal controls were 14.7% and 13.1% for 6 
E1G and 15.68% and 17.7% for PdG.  Urine samples were corrected for specific gravity using a 7 
hand refractometer (NSG Precision Cells, Inc., Farmingdale, NY) to account for hydration status.  8 
Urinary LH, assessed in ovulatory women only, was determined by double antibody 9 
radioimmunoassay (Diagnostic Products Corp., Los Angeles, CA). The sensitivity of the LH 10 
assay was 0.6 mIU L-1. The intra-assay and inter-assay coefficients of variation were 1.6% and 11 
7.1%, respectively. 12 
 13 
2.13  Statistics   14 
Data screening, conducted prior to statistical analysis included outlier detection, and 15 
examination of variable distributions within each of the three groups for normality. No outliers 16 
were detected, but adiponectin, leptin and urinary progesterone were determined to be positively 17 
skewed and were log transformed to approximate normal distribution.  All other data sets were 18 
normally distributed.  Comparison of data between all three groups were analyzed using one-way 19 
ANOVA, and when a significant main (fixed) effect was observed, the least significant squares 20 
was used to determine where the significant differences existed.   Multiple comparisons were 21 
adjusted by using Bonferroni methods.  Comparisons between two groups were analyzed using 22 
independent samples t-test.  Using pooled data, Pearson’s bivariate correlational analyses were 23 
used to determine significant linear independent associations between adiponectin, estrogen 24 
exposure, and all other variables of interest.  Running separate analyses, mixed model linear 25 
regression using stepwise methods (P=0.15 for entry, and P=0.20 to leave the model) were used 26 
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to explore predictors of gonadal status, adiponectin levels and bone health.  Variables included in 1 
the models were hormones and parameters of body composition of interest to the current study, as 2 
well as those that have been previously shown by others to be associated with each dependent 3 
variable of interest, regardless of whether significant bivariate correlations were observed 4 
between these variables and the dependent variable.  This method of inclusion was selected to 5 
account for potential confounding effects of various variables and to rule out the masking of 6 
associations of various independent variables with the dependent variable because of 7 
confounders.  Data were analyzed using packaged software (SPSS version 12.0; SPSS Inc., 8 
Chicago, IL).  A significance level of P<0.05 was used to detect the differences for statistical 9 
procedures.  The mean of 2-3 values for serum adiponectin, leptin, ghrelin, TT3, insulin, and 10 
urinary estrogen and progesterone for each subject were utilized in statistical analyses. All data 11 
are presented as the mean ± SEM. 12 
  13 
3.  RESULTS 14 
3.1  Participant Characteristics  15 
Participant characteristics are summarized in Table 1.  Groups did not differ (p>0.05) in 16 
age, height, weight and BMI.  All subjects were weight stable throughout the study period.  Age 17 
of menarche was similar (p>0.05) among all groups, but gynecologic age (chronologic age minus 18 
age of menarche; years) was lowest (p=0.024; main effect) in ExAmen (9.5 ± 1.4), compared 19 
with ExOv (12.6 ± 0.9) and SedOv (15.6 ± 1.8) women.  Average cycle length was 28.5 ± 0.8 and 20 
28.9 ± 0.7 days in the SedOv and ExOv groups, respectively. Average duration of amenorrhea for 21 
the ExAmen group was 247 ± 48 days.  Exercising groups had higher (p<0.001; main effect) 22 
cardiorespiratory fitness and lower (p<0.05; main effect) percent body fat, and total and central 23 
fat mass (kg) compared with sedentary women.  ExAmen trended toward lower (p=0.054; main 24 
effect) peripheral fat mass compared with SedOv.  REE adjusted for FFM was lower (p=0.002; 25 
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main effect) in ExAmen compared with all other groups.  Total BMD, L1-L4 BMD and L1-L4 Z-1 
score were lower (p<0.05; main effect) in ExAmen compared with ExOv.  2 
 3 
3.2  Serum Measures 4 
Serum measures are shown in Table 2.  Log adiponectin trended toward higher 5 
concentrations (p=0.056; main effect) in ExAmen compared with SedOv and ExOv women.  6 
When log adiponectin was adjusted for fat mass (kg), ExAmen had significantly higher (p=0.001; 7 
main effect) concentrations compared with all other groups (Figure 1).  As previously reported by 8 
our group [6, 20], serum leptin concentrations were lower (p=0.012; main effect) in exercising 9 
women (ExOv, 4.7 ± 0.7 ng/ml; ExAmen, 4.5 ± 1.0 ng/ml; log adjusted values) compared to 10 
sedentary women (9.3 ± 1.8 ng/ml).  Consistent with our previous data [25], serum ghrelin 11 
concentrations (pg/ml) were higher (p=0.011; main effect) in ExAmen (1939.7 ± 215.9) 12 
compared with SedOv (1385.2 ± 99.7) and ExOv (1397 ± 87.3), and serum TT3 (ng/dl) lower in 13 
ExAmen (89.1 ± 8.8), compared with SedOv (111.5 ± 2.7) and ExOv (103.3 ± 3.1).  Serum 14 
insulin concentrations were similar (4.7 ± 0.3 µIU/ml; pooled value; p=0.327; main effect) among 15 
the groups.   16 
 17 
3.3  Urinary Measures   18 
As previously reported by our group [6, 7] urinary E1G and log PdG exposure (see Table 19 
2), determined by the AUC trapezoidal method, was significantly lower (p=0.002 and p=0.001 for 20 
E1G and log PdG, respectively; main effects) in the ExAmen group compared with ExOv and 21 
SedOv groups across the menstrual cycle/monitoring period (Figure 2). E1G UC remained 22 
significantly lower in ExAmen after adjusting for fat mass.  LH levels, assessed in ovulatory 23 
women only, were similar (p>0.05) between SedOv and ExOv groups.   24 
 25 
 26 
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3.4  Adiponectin Correlates   1 
Using pooled data (Table 3), we report that regional fat mass (i.e., trunk and peripheral) 2 
and total fat mass, percent body fat, log adjusted leptin, ghrelin, TT3, REE adjusted for FFM, 3 
insulin and urinary E1G AUC measures are not correlated with log adiponectin in adult 4 
physically active and inactive women.  Log adiponectin adjusted for fat mass was also not 5 
associated with ghrelin, REE adjusted for FFM, TT3, insulin, and urinary E1G AUC.  In contrast, 6 
both log adiponectin and log adiponectin adjusted for fat mass were positively associated with 7 
age at menarche (r=0.461, p=0.006; r=0.352, p=0.048; respectively), and negatively associated 8 
with gynecologic age (r= -0.379, p=0.027; r= -0.489, p=0.005; respectively) and all bone 9 
measures (see Table 3).  As expected, log leptin was positively associated (p<0.05) with all 10 
indices of adiposity. In contrast, log adiponectin adjusted for fat mass (kg) was negatively 11 
associated (p<0.05) with all indices of adiposity.  12 
Examining each group independently, (i.e., SedOv, ExOv, and ExAmen), serum log 13 
adiponectin was not associated (p>0.05) with urinary E1G AUC, age, age at menarche, 14 
gynecologic age, insulin, ghrelin, TT3, REE adjusted for FFM, log leptin or measures of body fat 15 
in any group. In ExOv only, log adiponectin was inversely associated (p<0.05) with all bone 16 
measures, except total BMD (p=0.130).  For log adiponectin adjusted for fat mass, SedOv group 17 
only demonstrated negative associations with most measures of fat mass, including percent body 18 
fat (r = -0.730, p=0.026), central fat mass (r = -0.755, p=0.019), total fat mass (r = -0.741, 19 
p=0.022), and BMI (r = -0.799, p=0.010).  In ExAmen only, urinary E1G AUC trended toward a 20 
positive association with log adiponectin adjusted for fat mass (r=0.657, p=0.077).   21 
 22 
3.5  Predictors of Adiponectin  23 
Using pooled data for stepwise linear regression, we entered variables that have been 24 
previously reported to be associated with adiponectin, including leptin, ghrelin, fat mass, BMI, 25 
and nutritional status [8, 14, 17, 26].  Specifically, variables in the regression model included: 26 
  
14 
BMI, log leptin, ghrelin, TT3, and central and peripheral fat mass.  Both fat mass measures were 1 
included in the model to determine whether site specific body fat deposition predicted 2 
adiponectin levels.  No predictors of log adiponectin were identified.  In contrast, fat mass 3 
adjusted log adiponectin was predicted solely by trunkal fat mass (see Table 4), which explained 4 
~41% of the variance (adjusted R2=0.413, p<0.001).  Variables included in this model were the 5 
same as that for log adiponectin.  6 
 7 
3.6  Associations with, and Predictors of, Gonadal Status 8 
Using pooled data for bivariate analyses, nutritionally mediated metabolic indicators of 9 
energy deficiency, such as TT3 and REE adjusted for FFM, were independently and positively 10 
associated with E1G AUC in the current study (r= 0.463, p=0.007; r= 0.389, p=0.030, 11 
respectively).  In contrast, log leptin, ghrelin, and regional and total fat mass were not associated 12 
with E1G AUC.  Urinary log PdG AUC demonstrated positive associations with E1G AUC 13 
(r=0.575, p=0.001) and TT3 (r=0.419, p=0.014).  LH levels, assessed in ovulatory women only, 14 
did not correlate with any hormonal, nutritional, body compositional or bone health measures 15 
when analyzed using SedOv and ExOv women only.    16 
Due to detection of fewer significant correlates for PdG AUC or LH compared with E1G 17 
AUC, linear regression models for predictors of gondal status focused on E1G AUC.  Using 18 
pooled data for stepwise linear regression, we entered variables of interest, namely adiponectin, in 19 
addition to factors that have previously been reported to be associated with circulating estrogen 20 
levels, including total fat mass, TT3, leptin, and ghrelin [8, 14, 20].  For the first time, we report 21 
herein that in adult female athletes with secondary amenorrhea log adiponectin concentrations, 22 
both adjusted and unadjusted for fat mass, do not predict (p>0.05) estrogen exposure, and as such, 23 
fail to predict gonadal status.  Similarly, other nutritionally regulated hormones, such as log leptin 24 
and ghrelin, and total fat mass, do not predict gonadal status.  The strongest, and only, predictor 25 
of gonadal status was identified as TT3 (adjusted R2=0.228, p=0.004; see Table 4).    26 
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 1 
3.7  Associations with, and Predictors of, Bone Health 2 
Using pooled data, the current study shows that both lumbar and total BMD were 3 
significantly (p<0.05) negatively correlated with log adiponectin (Table 3; Figure 3).  Urinary 4 
E1G AUC trended (p=0.074) toward a significant positive association with L1-L4 BMD, but was 5 
not associated with total BMD. Using pooled data for stepwise linear regression, we entered log 6 
adiponectin, log leptin, ghrelin, insulin, E1G AUC, TT3 and BMI into two separate prediction 7 
models, one for L1-L4 BMD and one for total BMD.  All of the chosen variables have been 8 
previously shown to be associated with bone health in humans [27-31].  Log adiponectin and E1G 9 
AUC collectively contributed approximately 37% to the variability of L1-L4 BMD (adjusted 10 
R2=0.374, p=0.045; see Table 4).  Total BMD was negatively predicted by log adiponectin 11 
(adjusted R2 =0.188, p=0.009; see Table 4).  Although not determined to be an outlier, removal of 12 
the data point showing very high BMD and very low adiponectin (see Figure 3) did not 13 
significantly alter the predictors of bone health or the line of best fit between log adiponectin and 14 
L1-L4 BMD. 15 
 To account for the potential effects of exercise training on BMD [32], we examined bone 16 
health associations in exercising women only (ExOv and ExAmen). Both log adiponectin and log 17 
adiponectin adjusted for fat mass were significantly and negatively associated L1-L4 BMD (r= - 18 
0.612, p=0.002; r= -0.561, p=0.005, respectively) and total BMD (r= -0.542, p=0.008; r= -0.499, 19 
p=0.015; respectively).  E1G AUC trended toward a positive association with L1-L4 BMD (r = 20 
0.417; p=0.054).  Predictors of bone health in exercising women only were also carried out.  For 21 
both L1-L4 BMD and total BMD, each model was positively predicted by log adiponectin and 22 
E1G AUC (adjusted R2=0.467, F(1,19)=10.20, p=0.001; adjusted R2=0.333, F(1,29)=6.232, 23 
p=0.008; respectively).  Variables included in these models were the same as that used for the 24 
pooled data set. 25 
 26 
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4.  DISCUSSION 1 
The novel findings of this study are: 1) in comparison with adult eumenorrheic ovulatory 2 
sedentary and exercising women, physically active adult women with EDAA demonstrate 3 
elevated adiponectin concentrations relative to their fat mass; 2) log adiponectin adjusted for fat 4 
mass was predicted by trunkal fat mass; 3) lumbar bone health was predicted by log adiponectin 5 
and E1G AUC, while total body BMD was predicted solely by log adiponectin; and 4) the 6 
strongest predictor of gonadal status did not include secretory products of adipose tissue, namely 7 
adiponectin and leptin, but rather, nutritionally mediated metabolic hormones, specifically, TT3.  8 
While these data are associative in nature and do not relate to causality, these findings suggest 9 
that in physically active women with EDAA: 1) elevated adiponectin and hypoestrogenemia are 10 
independently, and in combination, associated with impaired bone health; 2) circulating 11 
adiponectin is not related to nutritionally or hormonally regulated factors or gonadal status, but is 12 
inversely associated with trunkal fat mass; and 3) nutritionally mediated metabolic hormones, 13 
specifically TT3, likely play a role in mediating gonadal status via energy deficiency related 14 
mechanisms. The clinical relevance of these findings is not yet known.  15 
 16 
4.1  Adiponectin in Amenorrheic Athletes 17 
In the current study, we report for the first time that ExAmen demonstrate elevated log 18 
adiponectin concentrations relative to their fat mass when compared with ExOv and SedOv 19 
women, supporting an inverse relationship between body fat and adiponectin concentrations. This 20 
finding is consistent with previous studies demonstrating an inverse relationship between serum 21 
adiponectin levels and parameters of overall adiposity, such as fat mass, BMI and percent fat 22 
mass in humans [12, 13]. It is also in agreement with data showing significantly elevated 23 
adiponectin adjusted for fat mass in female anorexia nervosa patients compared with healthy age-24 
matched adolescents [14]. In contrast, however, we report that log adiponectin concentrations that 25 
were not adjusted for fat mass were both similar between the groups and not related to whole or 26 
  
17 
regional fat mass.  While this observation is not in keeping with the reported inverse association 1 
between fat mass and adiponectin [12, 13], others have similarly reported both comparable 2 
adiponectin levels and no association between total fat mass and serum adiponectin in female 3 
adolescent athletes presenting with secondary and primary amenorrhea compared with their 4 
eumenorrheic counterpart [9]. No associations of adiponectin with total fat mass have also been 5 
reported in hypoestrogenic adolescent anorexia nervosa patients [14]. Reasons for equivocal 6 
findings in the current study, and the above studies [9, 12-14] are unclear, but may be related, in 7 
part, to a number of factors, including adjustment of adiponectin concentrations relative to fat 8 
mass, differences in the adiponectin assay used (i.e., high molecular weight versus total 9 
adiponectin), the chosen population, and gonadal status. 10 
 11 
4.2  Adiponectin and Bone 12 
Increases in BMD above levels seen in age-matched sedentary females are notably 13 
expressed in females between 20-25 years of age participating in load bearing exercise training 14 
[32].  In the present study, however, we report that despite participation in regular load-bearing 15 
exercise training, ExAmen women demonstrate lower lumbar and total BMD in association with 16 
elevated adiponectin levels.  Impaired bone health in weight-stable amenorrheic athletes has 17 
previously been shown to be associated with hypogonadism, particularly in the presence of an 18 
energy deficiency [30].  Consistent with this finding, we report here that E1G AUC was a 19 
significant contributor to our prediction model of L1-L4 BMD, and that ExAmen demonstrate 20 
significantly lower TT3 concentrations compared with SedOv and ExOv.  Low TT3 levels are 21 
recognized as a marker of under-nutrition and energy deficiency [6], indicating that the 22 
hypoestrogenic physically active women in the present study were likely energy deficient.  23 
Despite these alterations, we failed to demonstrate associations between bone health and TT3.  24 
Other factors known to impact bone health were also not associated with lumbar or total BMD, 25 
including ghrelin, leptin, and insulin.  This is of interest since ghrelin and insulin are known to 26 
  
18 
have stimulatory effects on osteoblastic activity [27, 28], and leptin is known to modulate bone 1 
turnover through complex central and peripheral effects [29].  In contrast, however, we report 2 
here, for the first time, that spine and total BMD are inversely associated with circulating log 3 
adiponectin concentrations in adult amenorrheic physically active women.  Similarly, other 4 
studies report decreased BMD in association with increased circulating adiponectin levels in 5 
adolescent hypoestrogenic amenorrheic anorexia nervosa patients [14], and adolescent 6 
amenorrheic female athletes [9]. These findings, and that of the current study, are in keeping with 7 
the documented stimulatory affect of adiponectin on osteoclastic activity in humans [33], but are 8 
in contrast to the reported increased osteoblastic and decreased osteoclastic activity in animal 9 
models [34]. Collectively, our findings and those of others [14, 27, 29, 33, 34] underscore the 10 
complexity of the interactions between nutritionally and metabolically regulated hormones in 11 
determining bone metabolism.  12 
 13 
4.3  Adiponectin and Gonadal Status 14 
Among our study groups, physically active women with EDAA demonstrated the lowest 15 
estrogen exposure and the highest adiponectin concentrations compared with ovulatory groups, 16 
suggesting a possible inhibitory role of estrogen on circulating adiponectin.  However, we failed 17 
to identify an association between urinary estrogen exposure over time and serum log adiponectin 18 
concentrations.  In agreement with this, others similarly document no correlation between serum 19 
adiponectin and estrogen levels among premenopausal and postmenopausal women [35], and 20 
among amenorrheic and eumenorrheic adolescent athletes [9].  Lack of association between 21 
estrogen and adiponectin concentrations in the current study suggests that estrogen deficiency in 22 
amenorrheic athletes is likely reflective of menstrual status per se and that other factors 23 
coincident with amenorrhea impact serum adiponectin levels in our chosen population. Such 24 
factors could include any combination of the well documented hormonal and metabolic 25 
alterations previously reported in amenorrheic athletes, including hypoglycemia [5], 26 
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hypoinsulinemia [5, 36], hypercortisolemia [5], hypothyroidemia [36], reduced REE [37], 1 
decreased ratio in measured versus predicted REE [10], lower leptin levels [36], and elevated 2 
ghrelin [25] and peptide YY [10] levels.  While we observed that TT3 and REE adjusted for FFM 3 
were independently associated with gonadal status, we did not detect any relationship with 4 
adiponectin, ghrelin, insulin, or leptin. This finding suggests that metabolic rather than 5 
nutritionally regulated factors may mediate gonadal status in adult amenorrheic physically active 6 
premenopausal women.  7 
 8 
4.4  Adiponectin and Body Fat Distribution 9 
In keeping with the well documented effect of regular physical activity on body 10 
composition, we observed greater central and peripheral fat mass in sedentary women compared 11 
with exercising women.  Specifically, ExAmen women demonstrated significantly lower regional 12 
and total fat mass compared with SedOv, and non-significantly lower regional and total fat mass 13 
compared with ExOv women.  Similar body composition in amenorrheic athletes has been 14 
previously reported [6, 20, 25].  Using pooled data, trunkal fat mass, but not peripheral fat mass 15 
or whole body fat mass, was inversely predicted by log adiponectin adjusted for fat mass. This 16 
finding is consistent with recent in vitro evidence demonstrating that the rate of adiponectin 17 
secretion is approximately threefold higher from visceral compared with subcutaneous fat [16]. 18 
Similarly, others have also reported an inverse association between serum adiponectin and 19 
visceral fat [38].  These findings [16, 38], and that of the current study, supports the postulate that 20 
distribution of body fat rather than total fat amount may be important to adiponectin metabolism.  21 
This hypothesis awaits further investigation. 22 
 23 
4.5  Limitations 24 
While the primary objectives of this study were to examine serum adiponectin levels in 25 
physically active women with EDAA and to examine whether this nutritionally regulated 26 
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hormone could predict gonadal status or bone health, the current study only examines 1 
associations, not cause and effect.  In addition, our chosen method to determine predictors of 2 
adiponectin, gonadal status and bone health may not be optimal.  As such, these associations and 3 
predictions should be interpreted appropriately. We also failed to examine differences between 4 
varying molecular weight adiponectin molecules, and we did not examine all possible urinary 5 
estrone conjugates.  It is possible that differences exist between low, medium, high, and total 6 
molecular weight adiponectin, and between the different estrone conjugates in adult amenorrheic 7 
athletes.  Finally, our study groups were of small sample size, and may have therefore affected 8 
our ability to detect true associations where present.  As such, our findings should be interpreted 9 
prudently.  10 
 11 
5.  CONCLUSION 12 
We demonstrate for the first time that total serum adiponectin levels relative to fat mass 13 
are elevated in exercising adult premenopausal women with EDAA. While this elevation does not 14 
predict gonadal status, as determined by estrogen exposure across time, increased adiponectin 15 
concentrations and estrogen exposure were independently, and in combination, associated with 16 
impaired bone health.  Adiponectin relative to fat mass was also inversely associated with trunkal 17 
fat mass, implying that body fat distribution rather than total body fat mass may be important in 18 
determining adiponectin concentrations.  Markers of nutritionally mediated metabolic status, 19 
namely TT3, predicted estrogen exposure, suggesting that metabolic factors likely mediate 20 
gonadal status via energy deficiency related mechanisms.  Although mechanisms and 21 
consequences of elevated adiponectin concentrations in amenorrheic athletes remain to be 22 
elucidated, the results of this study further characterize the unique endocrine profile of these 23 
women. 24 
 25 
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Figure 1. Bar chart showing serum adiponectin levels adjusted for fat mass (mg/L/kg) among the 1 
study groups.  * p=0.001 (main effect) ExAmen vs SedOv and ExOv. 2 
 3 
Figure 2.  Bar chart showing estrogen exposure across the menstrual cycle, or 30-day monitoring 4 
period, by means of daily urinary E1G area under the curve analysis for each study group.   5 
* p=0.002 (main effect) ExAmen vs SedOv and ExOv. 6 
 7 
Figure 3.  Scatterplot showing the relationship between lumbar spine BMD (g/cm2) and log 8 
adiponectin concentrations (ng/mL) for all groups (r = -0.538; p=0.001; R2=0.289). 9 
 10 
Table 1.  Subject characteristics of the study groups. 
  SedOv ExOv ExAmen P (main  
  (n=10) (n=15) (n=9) effect) 
Demographics     
Age (years) 27.8 ± 1.8 24.7 ± 0.9 24.0 ± 1.5 0.146 
Age of menarche (years) 12.5 ± 0.4 12.2 ± 0.3 13.3 ± 0.6 0.177 
Gynecologic age (years) 15.6 ± 1.8 12.6 ± 0.9 9.5 ± 1.4a 0.024 
Weight (kg) 58.2 ± 2.4 57.5 ± 1.3 57.5 ± 2.0 0.952 
Height (cm) 161.6 ± 1.6 164.8 ± 1.3 165.3 ± 1.3 0.181 
BMI (kg/m2) 22.4 ± 0.8 21.3 ± 0.4 21.1 ± 0.7 0.279 
Body fat total (%) 31.0 ± 2.2b 24.3 ± 1.3 19.9 ± 2.2 0.002 
Body FM total (kg) 17.6 ± 1.9b 13.3 ± 0.9 11.2 ± 1.5 0.014 
Trunk FM (kg) 8.53 ± 1.03b 6.2 ± 0.6 4.9 ± 0.7 0.010 
Peripheral FM (kg) 8.4 ± 0.9 6.6 ± 0.4 5.8 ± 0.8 0.054 
VO2 max (ml/kg/min) 38.6 ± 1.3b 46.3 ± 1.3 45.4 ± 1.2 0.001 
REE/FFM (kcal/day/kg) 33.4 ± 0.9 31.9 ± 0.7 28.7 ± 0.9a 0.002 
L1-L4 BMD (g/cm2) 1.18 ± 0.04 1.28 ± 0.05 1.11 ± 0.04c 0.026 
L1-L4 BMD Z-score 0.19 ± 0.30 1.05 ± 0.40 -0.48 ± 0.2c 0.015 
Total BMD (g/cm2) 1.14 ± 0.02 1.20 ± 0.02 1.13 ± 0.02c 0.028 
Total BMD Z-score 0.47 ± 0.22 1.24 ± 0.22d 0.34 ± 0.27 0.019 
Values are mean ± SEM. BMI, body mass index; VO2 max, maximal oxygen uptake; EIG, 
urinary estrone 3-glucuronide; AUC, area under the curve; FM, fat mass; REE, resting energy 
expenditure; FFM, fat free mass; BMD, bone mineral density. 
a ExAmen vs. SedOv & ExOv 
b SedOv vs. ExOv & ExAmen  
c ExAmen vs. ExOv 
d ExOv vs. ExAmen and SedOv 
 
Table 2.  Reproductive hormones and serum measures for the study groups. 
 
  SedOv ExOv ExAmen P (main  
  (n=10) (n=15) (n=9) effect) 
Reproductive Hormones     
E1G AUC (ng/ml) 1864.9 ± 232.7 2047.9 ± 256.4 648.9 ± 160.3a 0.002 
E1G AUC/FM (ng/ml/kg) 126.6 ± 25.4 173.3 ± 23.9 69.9 ± 17.2b 0.019 
     
Serum Measures     
Adiponectin (mg/L) 8.2 ± 0.8 9.4 ± 1.3 14.4 ± 2.7c 0.028 
Adiponectin/FM (mg/L/kg) 0.5 ± 0.1 0.7 ± 0.1 1.4 ± 0.2a <0.001 
Log Adiponectin (mg/L) 3.8 ± 0.1 3.9 ± 0.1 4.1 ± 0.1a 0.056 
Log Adiponectin/FM (mg/L/kg) 2.7 ± 0.1 2.8 ± 0.1 3.1 ± 0.1a 0.001 
Values are mean ± SEM. BMI, body mass index; VO2 max, maximal oxygen uptake; EIG, 
urinary estrone 3-glucuronide; AUC, area under the curve; FM, fat mass. 
a ExAmen vs. SedOv & ExOv 
b ExAmen vs. ExOv 
c ExAmen vs. SedOv 
 
Table 3: Bivariate correlates between hormones, body composition and bone health.* 
 
  E1G 
AUC  
Log 
Leptin TT3 Ghrelin Insulin 
Total 
FM 
Trunk 
FM  
Periph. 
FM  
REE/ 
FFM  
L1-L4 
BMD  
Total 
BMD  
Log Adipon. 
(mg/L) 
r=-0.014 
p=0.940 
r=0.162      
p= 0.353 
r=0.200 
p=0.249 
r=0.030 
p=0.865 
r=-0.239 
p=0.166 
r=0.003      
p= 0.987 
r=0.098      
p= 0.589 
r=0.114 
p=0.529 
r=-0.106 
p=0.558 
r=-0.538 
p=0.001 
r=-0.440 
p=0.010 
E1G AUC 
(ng/ml) - 
r=0.021 
p=0.906 
r=0.463 
p=0.007 
r=0.097 
p=0.593 
r=-0.003 
p=0.985 
r=0.071 
p=0.705 
r=0.117 
p=0.531 
r=0.071 
p=0.705 
r=0.389 
p=0.030 
r=0.320 
p=0.074 
r=0.182 
p=0.328 
Log Leptin 
(ng/ml)  - 
r=0.309 
p=0.070 
r=-0.202 
p=0.245 
r=0.228 
p=0.189 
r=0.743 
p=0.000 
r=0.681 
p=0.000 
r=0.731 
p=0.000 
r=0.479 
p=0.005 
r=-0.105 
p=0.556 
r=-0.113 
p=0.532 
TT3 (ng/dl) 
  - 
r=-0.242 
p=0.161 
r=0.277 
p=0.108 
r=0.350 
p=0.046 
r=0.308 
p=0.082 
r=0.359 
p=0.040 
r=0.406 
p=0.019 
r=0.008 
p=0.963 
r=0.086 
p=0.636 
Ghrelin 
(pg/ml)    - 
r=-0.106 
p=0.544 
r=-0.260 
p=0.143 
r=-0.310 
p=0.079 
r=-0.173 
p=0.337 
r=-0.407 
p=0.017 
r=0.029 
p=0.869 
r=0.145 
p=0.422 
Insulin 
(uIU/ml)     - 
r=0.056 
p=0.756 
r=0.096 
p=0.597 
r=0.001 
p=0.997 
r=0.281 
p=0.113 
r=0.247 
p=0.158 
r=0.121 
p=0.502 
Total FM 
(kg)      - 
r=0.944 
p=0.000 
r=0.955 
p=0.000 
r=0.524 
p=0.002 
r=-0.138 
p=0.443 
r=0.004 
p=0.983 
Trunk FM 
(kg)       - 
r=0.804 
p=0.000 
r=0.595 
p=0.000 
r=-0.133 
p=0.460 
r=0.022 
p=0.904 
Peripheral 
FM (kg)        - 
r=0.603 
p=0.000 
r=-0.126 
p=0.486 
r=-0.011 
p=0.949 
REE/FFM 
(kcal/day/kg)         - 
r=-0.092 
p=0.612 
r=-0.191 
p=0.286 
L1-L4 BMD 
(g/cm2)                   - 
r=0.902 
p=0.000 
Adipon, adiponectin; EIG, urinary estrone 3-glucuronide; AUC, area under the curve; TT3, total triiodothyronine; FM, fat mass;  
Periph, peripheral; REE, resting energy expenditure; FFM, fat free mass; BMD, bone mineral density. 
* Using pooled data (all women, n=34).  Significant correlations are bolded. 
 
Table 4. Regression analysis (stepwise regression) of predictors of adiponectin*, 
estrogen exposure, and bone mineral density. 
 
    B SE B β F ratio R2 R2 adj P 
Adiponectin*/FFM        
 Intercept 3.273 0.093      
 Trunk Fat Mass -0.065 0.013 -0.657 23.538 0.432 0.413 <0.001 
         
Estrogen Exposure        
 Intercept -10138.32 3769.86      
 TT3 5920.38 1883.09 0.504 9.885 0.254 0.228 0.004 
         
Total BMD        
 Intercept 1.803 0.227      
 Adiponectin* -0.161 0.057 -0.464 7.948 0.215 0.188 0.009 
         
L1-L4 BMD        
 Intercept 2.728 0.414      
 Adiponectin* -0.406 0.104 -0.565 13.683 0.321 0.297 0.001 
  E1G AUC 0.048 0.000 0.304 9.856 0.413 0.374 0.045 
All women, n=34. 
* signifies log adjusted data 
Figure 1 
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Figure 3 
 
 
 
 
 
R2=0.289 
